Debt target: Sub-500 crores by May 2026
Management has line of sight to reduce closing debt below 500 crores post receipt of final regulatory comments, building on the 146 crore reduction already achieved.
SOLARA / guidance tracker
Keep management guidance in view.
Solara Active Pharma Sciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
debt_reduction
Visak plant revival: 5-6 months timeline
Mothballed Visak facility (FDA-approved) to be converted from single-product ibuprofen plant to multi-purpose plant with a high-potent API block, targeting commercial production revival within 5-6 months.
Strategic review conclusion: Q4 FY26
External advisor recommendations on ibuprofen business (including sale, cost restructuring, or technical intervention) to be presented alongside Q4 FY26 results by end of April.
Ibuprofen strategic options to be finalized in H1 FY27
Bankers appointed to evaluate strategic options for ibuprofen business; process expected to conclude in H1 FY27.
Debt-free target by FY29
Management aims to make Solara debt-free (including working capital) by FY29.
4-5 DMF filings per year starting FY27
Company plans to file 4-5 Drug Master Files annually, with first filed in April 2026.